Philip Morris stock price target raised to $200 from $188 at Citi

Published 10/07/2025, 11:38
© Reuters

Investing.com - Citi has raised its price target on Philip Morris (NYSE:PM) to $200.00 from $188.00 while maintaining a Buy rating on the tobacco company’s stock. The tobacco giant, currently valued at $277 billion, has seen its shares surge over 54% in the past six months, trading near its 52-week high of $186.69.

The research firm expects Philip Morris to demonstrate impressive performance across its businesses in the second quarter, with strong ZYN volumes supported by capacity that came back online from late March.

Citi projects Q2 organic sales growth of 7% and operating income growth of 11%, which falls comfortably within the company’s guidance ranges. The firm also anticipates Q2 adjusted earnings per share of $1.86, exceeding the company’s guided range of $1.80-$1.85.

Looking ahead, Citi expects Philip Morris management to maintain its full-year organic revenue and operating income guidance ranges for now, but anticipates recent positive foreign exchange movements will prompt an upgrade to the FY25 adjusted EPS range to $7.45-$7.58 from the previous $7.36-$7.49.

Despite the strong year-to-date share price performance, Citi reiterated its Buy rating, citing ongoing near-term positive earnings momentum and increasing upside potential from multi-category expansion, including in the vape segment.

In other recent news, Philip Morris International has reaffirmed its 2025 profit forecast, projecting a full-year reported diluted earnings per share (EPS) between $7.01 and $7.14. This forecast, which includes a positive currency impact, indicates a projected currency-neutral growth of 10.5% to 12.5%. Additionally, BofA Securities has increased its price target for Philip Morris to $200, maintaining a Buy rating, following positive remarks from the company’s CFO on their smoke-free strategy. Jefferies also initiated coverage with a Buy rating and a $220 price target, highlighting the company’s leadership in heated tobacco and oral nicotine segments. Meanwhile, Stifel has reiterated its Buy rating with a $186 price target, emphasizing the importance of the European market for smoke-free growth. UBS analysts have maintained a Neutral rating, noting improvements in the U.S. market for the ZYN nicotine pouches. These developments reflect ongoing confidence in Philip Morris’s strategic direction and growth potential in smoke-free products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.